The fair value of the Company's available-for-sale investments at

, and were million and million, respectively. The increase was caused by the addition of

million in corporate bond securities held by Advanced Cell Diagnostics (ACD), and the investment of

million of available cash in China into certificates of deposit. The remaining difference is due to a

million change in the fair value of the Company's investment in ChemoCentryx, Inc. (CCXI). The amortized cost basis of the Company's investment in CCXI at and was million.

 

 

Inventories consist of (in thousands):

 

 

At the Company had million of inventory compared to million as of The increase from is primarily due to

million of additional inventory at ACD which was acquired on At both and the Company had approximately million of excess protein, antibody and chemically-based inventory on hand which was not valued. The inventory reserves represent the cumulative write-down of inventory to

the lower of cost or market at the close of a fiscal period. The write-down of inventory creates a new cost basis that subsequently is not marked-up based on changes in underlying facts and circumstances.

 

Property and equipment consist of (in thousands):

 

 

Intangible assets consist of (in thousands):         

                          

 

Changes to the carrying amount of net intangible assets for the months ended consist of (in thousands):

 

 

The estimated future amortization expense for intangible assets as of is as follows (in thousands):

 

 

Changes to the carrying amount of goodwill for the months ended consist of (in thousands):

 

 

We evaluate the carrying value of goodwill in the quarter of each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company used a “step qualitative test to assess of its reporting units during the quarter for fiscal year The estimated fair values of these reporting units using “step testing substantially exceeded their respective carrying values. The company elected to utilize a “step quantitative test for the Protein Platforms reporting unit given that this is a newer reporting unit created primarily through acquisitions. Based on the “step testing performed, no adjustment to the carrying value of goodwill was necessary. All of the reporting units had substantial headroom as of

 

No triggering events were identified during the months ended There has been impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC guidance for goodwill and other intangibles on

.

 

 

Other Assets consist of (in thousands):

 

 

At the Company had

million of other assets compared to million as of The increase from is due to a

million investment in Astute Medical, Inc

. during the quarter of fiscal year This investment is accounted for under the cost-method as we own less than of the outstanding stock and we concluded that we do not have significant influence. Under the cost-method, the fair value is not estimated if there are no identified events or changes in circumstances that have a significant adverse effect on the fair value of the investment. No such events or changes in circumstances were identified in the period ended

.